Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy
Nils von Hentig HIV Center, Medical Department II, Hospital of the JW Goethe-University, Frankfurt, BAG Darab-Kaboly/von Hentig, General Medicine and HIV Care, Frankfurt am Main, Germany Abstract: The pharmacoenhancement of plasma concentrations of protease inhibitors by coadministration of so-calle...
Guardado en:
Autor principal: | von Hentig N |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/954ef647f6c445ce81d4960adf07588a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS
por: Navarro J, et al.
Publicado: (2016) -
Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection
por: Crutchley RD, et al.
Publicado: (2016) -
Increased incidences of noninfectious comorbidities among aging populations living with human immunodeficiency virus in Ecuador: a multicenter retrospective analysis
por: Hernández I, et al.
Publicado: (2019) -
Combine therapy as a modern approach to treatment of allergic rhinitis
por: Alexander V. Emelyanov
Publicado: (2021) -
Maximum Medical Therapy: Brinzolamide/Brimonidine And Travoprost/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension
por: Lerner SF, et al.
Publicado: (2019)